{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:46:00Z","timestamp":1792453560072,"version":"4.5.0"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0013792","type":"journal-article","created":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T19:38:00Z","timestamp":1288640280000},"page":"e13792","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":50,"title":["Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1\/OATP1B1 in Flavopiridol Disposition"],"prefix":"10.1371","volume":"5","author":[{"given":"Wenjun","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunyan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunjoo","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Farley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jarjoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Sadee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Grever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch A.","family":"Phelps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2010,11,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jnci\/92.5.376","article-title":"Preclinical and clinical development of cyclin-dependent kinase modulators.","volume":"92","author":"AM Senderowicz","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"ref2","first-page":"4634","article-title":"Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.","volume":"59","author":"B Carlson","year":"1999","journal-title":"Cancer Res"},{"key":"ref3","first-page":"2973","article-title":"Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.","volume":"56","author":"BA Carlson","year":"1996","journal-title":"Cancer Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/0006-2952(93)90590-S","article-title":"Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity.","volume":"46","author":"PJ Worland","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.cdd.4400868","article-title":"The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway.","volume":"8","author":"RH Decker","year":"2001","journal-title":"Cell Death Differ"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood.V91.2.458","article-title":"Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol.","volume":"91","author":"BW Parker","year":"1998","journal-title":"Blood"},{"key":"ref7","first-page":"3527","article-title":"The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.","volume":"8","author":"I Gojo","year":"2002","journal-title":"Clin Cancer Res"},{"key":"ref8","first-page":"93","article-title":"Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis.","volume":"63","author":"S Wittmann","year":"2003","journal-title":"Cancer Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood.V92.10.3804","article-title":"Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.","volume":"92","author":"JC Byrd","year":"1998","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V84.9.3148.3148","article-title":"p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.","volume":"84","author":"E Wattel","year":"1994","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1200\/JCO.1998.16.9.2986","article-title":"Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.","volume":"16","author":"AM Senderowicz","year":"1998","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/10428190290016908","article-title":"Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma.","volume":"43","author":"TS Lin","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1345\/aph.1C404","article-title":"Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.","volume":"37","author":"MA Rudek","year":"2003","journal-title":"Ann Pharmacother"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00280-002-0527-2","article-title":"Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.","volume":"50","author":"JP Thomas","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2002.08.080","article-title":"Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.","volume":"20","author":"GK Schwartz","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1200\/JCO.2009.22.6944","article-title":"Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.","volume":"27","author":"TS Lin","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood-2008-07-168583","article-title":"Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.","volume":"113","author":"MA Phelps","year":"2009","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"610","DOI":"10.5414\/CPP41610","article-title":"The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapy.","volume":"41","author":"W Jager","year":"2003","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1016\/S0024-3205(03)00699-4","article-title":"Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2).","volume":"73","author":"W Jager","year":"2003","journal-title":"Life Sci"},{"key":"ref20","first-page":"3320","article-title":"Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients.","volume":"9","author":"T Nakanishi","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref21","first-page":"145","article-title":"Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr\/BCrp\/ABCP1), in flavopiridol-resistant human breast cancer cells.","volume":"7","author":"RW Robey","year":"2001","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1038\/sj.onc.1206938","article-title":"Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).","volume":"22","author":"LA Doyle","year":"2003","journal-title":"Oncogene"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1124\/mol.64.6.1452","article-title":"Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis.","volume":"64","author":"T Nakanishi","year":"2003","journal-title":"Mol Pharmacol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1349-7006.2005.00081.x","article-title":"Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics\/pharmacodynamics.","volume":"96","author":"Y Sugimoto","year":"2005","journal-title":"Cancer Sci"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1023\/A:1015341726183","article-title":"In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes.","volume":"19","author":"J Ramirez","year":"2002","journal-title":"Pharm Res"},{"key":"ref26","first-page":"407","article-title":"In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9.","volume":"29","author":"B Hagenauer","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1208\/ps0303_commentary2","article-title":"UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof.","volume":"3","author":"S Mani","year":"2001","journal-title":"AAPS PharmSci"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/03602530600739835","article-title":"Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.","volume":"38","author":"S Nagar","year":"2006","journal-title":"Drug Metab Rev"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00001813-200302000-00006","article-title":"Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.","volume":"14","author":"S Zhai","year":"2003","journal-title":"Anticancer Drugs"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1124\/jpet.103.054072","article-title":"Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs.","volume":"307","author":"L Villeneuve","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"ref31","first-page":"3400","article-title":"Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.","volume":"6","author":"F Innocenti","year":"2000","journal-title":"Clin Cancer Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1755-8794-1-24","article-title":"Genotyping panel for assessing response to cancer chemotherapy.","volume":"1","author":"Z Dai","year":"2008","journal-title":"BMC Med Genomics"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2008.20.6300","article-title":"Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.","volume":"27","author":"F Innocenti","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/clpt.2008.63","article-title":"Pharmacogenetic pathway analysis of irinotecan.","volume":"84","author":"GL Rosner","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0169-2607(98)00098-4","article-title":"A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models.","volume":"59","author":"J Parke","year":"1999","journal-title":"Comput Methods Programs Biomed"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/jpet.104.068056","article-title":"Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans.","volume":"311","author":"M Hirano","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jchromb.2008.04.023","article-title":"Development and validation of a sensitive liquid chromatography\/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule.","volume":"868","author":"MA Phelps","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref38","article-title":"Development and Validation of a Highly Sensitive Liquid Chromatography\/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma.","author":"Q Liu","year":"2008","journal-title":"Ther Drug Monit"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0091270007309563","article-title":"Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.","volume":"47","author":"N Chen","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jpba.2004.09.053","article-title":"A simple and sensitive LC\/MS\/MS assay for 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and tissues: application to pharmacokinetic study of liposome entrapped SN-38 (LE-SN38).","volume":"37","author":"S Khan","year":"2005","journal-title":"J Pharm Biomed Anal"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1124\/dmd.104.001909","article-title":"Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.","volume":"33","author":"T Nozawa","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","article-title":"Stability and performance of a population pharmacokinetic model.","volume":"37","author":"EI Ette","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1200\/JCO.2009.22.6944","article-title":"Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease.","volume":"27","author":"TS Lin","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2217\/pgs.09.88","article-title":"Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.","volume":"10","author":"L Elens","year":"2009","journal-title":"Pharmacogenomics"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jnutbio.2008.07.005","article-title":"Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease.","volume":"20","author":"S Sookoian","year":"2009","journal-title":"J Nutr Biochem"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","article-title":"NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity.","volume":"112","author":"L Wojnowski","year":"2005","journal-title":"Circulation"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/clpt.2009.197","article-title":"Transporter pharmacogenetics and statin toxicity.","volume":"87","author":"M Niemi","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00280-008-0864-x","article-title":"Life-threatening toxicities in a patient with UGT1A1*6\/*28 and SLCO1B1*15\/*15 genotypes after irinotecan-based chemotherapy.","volume":"63","author":"H Takane","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development.","volume":"9","author":"KM Giacomini","journal-title":"Nat Rev Drug Discov"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/14622416.9.1.19","article-title":"Global analysis of genetic variation in SLCO1B1.","volume":"9","author":"MK Pasanen","year":"2008","journal-title":"Pharmacogenomics"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/tpj.2009.54","article-title":"The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.","volume":"10","author":"SP Romaine","year":"2010","journal-title":"Pharmacogenomics J"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0013792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T12:07:57Z","timestamp":1592050077000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0013792"}},"subtitle":[],"editor":[{"given":"Ulrich","family":"Zanger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,11,1]]},"references-count":51,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2010,11,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0013792","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,1]]}}}